Relation of CYP2C19 loss-of-function polymorphism to the occurrence of stent thrombosis

Betti Giusti, Anna Maria Gori, Rossella Marcucci, Rosanna Abbate

Research output: Contribution to journalArticlepeer-review

Abstract

Importance of the field: Major adverse cardiovascular events including stent thrombosis associated with residual platelet reactivity on antiplatelet treatment in high risk vascular patients is a hot issue that needs a strong effort to be solved. Dual antiplatelet therapy with clopidogrel and aspirin prevents ischemic events and improves outcomes following acute coronary syndromes and percutaneous coronary intervention. However, adverse cardiovascular events occur in these patients, and several studies have shown that patients who suffer cardiovascular complications have high post-treatment platelet reactivity despite antiplatelet treatment. Clopidogrel requires conversion to active metabolite by CYP isoenzymes. Recently, CYP2C19*2 polymorphism (G681A nucleotide substitution) has been shown to be associated with decreased metabolisation of clopidogrel, poor antiaggregant effect and increased adverse cardiovascular events. Areas covered in this review: This review summarises the principal studies contributing to establish the relationship between CYP2C19*2 polymorphism and adverse outcomes in high risk patients on clopidogrel treatment. Take home message: Prospective studies are urgently needed to determine the clinical impact of a score that takes into account individual characteristics of patients - CYP2C19*2 genotypes, residual platelet reactivity, drugdrug interaction, as well as traditional and procedural risk factors - for the identification of the therapeutic strategy that provides the best benefit for the single subject.

Original languageEnglish
Pages (from-to)393-407
Number of pages15
JournalExpert Opinion on Drug Metabolism and Toxicology
Volume6
Issue number4
DOIs
Publication statusPublished - Apr 2010

Keywords

  • Acute coronary syndromes
  • Antiaggregant therapy
  • Aspirin
  • Clopidogrel
  • CYP2C19 loss-of-function polymorphism
  • Drug eluting stent
  • Major adverse cardiovascular events
  • Percutaneous coronary interventions
  • Stent thrombosis

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology

Fingerprint Dive into the research topics of 'Relation of CYP2C19 loss-of-function polymorphism to the occurrence of stent thrombosis'. Together they form a unique fingerprint.

Cite this